





Item 8.01. Other Events.

On September 5, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing that target enrollment for the UNITY-CLL Phase 3 trial has been achieved. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated September 5, 2017.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: September 5, 2017

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer



INDEX TO EXHIBITS

Exhibit  
Number Description

99.1 Press Release, dated September 5, 2017.